Harvard sues Trump over frozen research funding

22 April 2025

Harvard University has filed a lawsuit against the US government after more than $2 billion in federal research funding was suspended, disrupting a range of biomedical and public health projects. The legal challenge, announced Monday, marks an escalation in a standoff with the Trump administration over new policy demands tied to continued grant access.

The university is seeking to reverse what it claims is an unlawful freeze on contracts and grants from agencies including the National Institutes of Health and the Biomedical Advanced Research and Development Authority.

The lawsuit contends that the administration's move violates constitutional protections and undermines the scientific independence of academic institutions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK